耐铁的脂肪细胞通过GPX4-介导的脂肪细胞-半酶转换和铁-胺代谢通信驱动化细胞的发生
Xiangguang Shi1,2,3,4, Xueyi Xia5, Yang Xiao5
1Department of Dermatology, Huashan Hospital, Deptartment of Allergy and immunology, Huashan Hospital, and Research Center of Allergy and Diseases, Shanghai Institute of Dermatology, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, China.
International journal of biological sciences
|August 27, 2025
概括
状纤维化是由促进原蛋白生产的耐铁细胞驱动的. 用诱导剂或铁化剂向铁化是一种有前途的新治疗策略.
科学领域:
- 纤维化研究
- 细胞代谢
- 皮肤病学
背景情况:
- 形体是一种严重的纤维化疾病,治疗干预措施有限.
- 了解皮质脂肪细胞和铁死耐药性至关重要.
- 研究脂肪细胞和纤维细胞在化形成中的相互作用是必不可少的.
研究的目的:
- 阐明质病变的机制,特别是皮肤脂肪细胞的作用.
- 检查脂肪细胞中铁性耐药性对 keloid 纤维化的贡献.
- 探索潜在的治疗策略,以向化体中的化途径.
主要方法:
- 单细胞RNA测序 (scRNA-seq) 用于识别基质组织中的关键细胞群.
- 对脂肪细胞中铁过载,活性氧物种 (ROS) 耗尽和干扰素反应的机制研究.
- 在脂肪细胞-介酶过渡 (AMT) 中评估氨酸过氧酶4 (GPX4) 表达和TGF-β信号;体内测试铁酶诱导剂 (RSL3) 和铁化剂 (DFO).
主要成果:
- scRNA- seq 确定了耐铁的脂肪细胞是 keloid 发病的关键驱动因素,显示铁过载和干扰素反应受损.
- 脂肪细胞中的GPX4表达升高通过铁依赖的TGF-β信号促进AMT,增强纤维细胞原蛋白的产生.
- 观察到脂肪细胞和纤维细胞之间的代谢共生,涉及铁和囊的交换,放大亲纤维反循环;RSL3和DFO治疗在体内减弱了 keloid 的生长.
结论:
- 一个新的脂肪细胞中心机制涉及GPX4介导的铁灭抵抗,代谢共生和干扰的干扰信号传递.
- 通过RSL3或铁化等药物进行铁化调节,为反抗性质状况提供了有前途的治疗策略.
- 针对这种脂肪细胞-纤维细胞交叉声提供了开发有效化物治疗的新途径.
更多相关视频
相关概念视频
01:16Necrosis
4.8K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K